64 related articles for article (PubMed ID: 8752147)
1. delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
McClay EF; Winski PJ; Jones JA; Jennerette J; Gattoni-Celli S
Cancer Res; 1996 Sep; 56(17):3866-9. PubMed ID: 8752147
[TBL] [Abstract][Full Text] [Related]
2. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
4. Effects of indomethacin, cisplatin and delta 12-prostaglandin J2 on growth of oral squamous carcinoma cells.
el Attar TM; Virji AS
Anticancer Res; 1997; 17(6D):4399-402. PubMed ID: 9494540
[TBL] [Abstract][Full Text] [Related]
5. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cisplatin resistance in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549].
Zhang X; Li Q; Han Y; Liu Z
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):537-9. PubMed ID: 12667319
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antiproliferative effect of delta 12-prostaglandin J2 (delta 12-PGJ2) and hyperthermia on human esophageal cancer cell lines.
Yokoyama Y; Saito M; Saito T; Yuguchi T; Sawataishi M; Sakamoto T; Tazawa K; Tsukada K
Hum Cell; 2000 Mar; 13(1):23-33. PubMed ID: 10937344
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
11. The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.
Haslmayer P; Thalhammer T; Jäger W; Aust S; Steiner G; Ensinger C; Obrist P
Int J Oncol; 2002 Oct; 21(4):915-20. PubMed ID: 12239635
[TBL] [Abstract][Full Text] [Related]
12. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Jones JA; Albright KD; Christen RD; Howell SB; McClay EF
Cancer Res; 1997 Jul; 57(13):2657-60. PubMed ID: 9205073
[TBL] [Abstract][Full Text] [Related]
13. Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen?
Mohammed MQ; Photiou A; Shah P; Retsas S
Anticancer Res; 1995; 15(4):1319-26. PubMed ID: 7654015
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells.
Bowen D; Southerland WM; Hawkins M; Johnson DH
Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
19. Protection by cycloheximide against cytotoxicity induced by vincristine, colchicine, or delta 12-prostaglandin J2 on human osteosarcoma cells.
Sakai T; Aoike A; Marui N; Kawai K; Nishino H; Fukushima M
Cancer Res; 1989 Mar; 49(5):1193-6. PubMed ID: 2917351
[TBL] [Abstract][Full Text] [Related]
20. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure.
Chatterjee PK; Patel NS; Cuzzocrea S; Brown PA; Stewart KN; Mota-Filipe H; Britti D; Eberhardt W; Pfeilschifter J; Thiemermann C
Cardiovasc Res; 2004 Feb; 61(3):630-43. PubMed ID: 14962493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
